임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
26건 표시
- 2상모집 중단 (진행 중)· B-cell Acute Lymphoblastic LeukemiaA Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
협력: 암젠
- 2상모집 중단 (진행 중)· Metastatic Gastro-esophageal AdenocarcinomaBemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
협력: 암젠
- 2상모집 중단 (진행 중)· Soft Tissue SarcomaNeoadjuvant Intralesional Injection of Talimogene Laherparepvec
협력: 암젠
- 2상모집 중단 (진행 중)· Small Cell Lung Cancer (SCLC)A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
리드: 암젠
- 2상모집 중단 (진행 중)· MTAP-deleted NSCLCA Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
리드: 암젠
- 2상모집 중단 (진행 중)· Type 2 Diabetes Mellitus (T2DM)A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
리드: 암젠
- 2상모집 중단 (진행 중)· Extensive Stage Small Cell Lung CancerStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
리드: 암젠
- 2상모집 중단 (진행 중)· B Precursor Acute Lymphoblastic LeukemiaStudy of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
리드: 암젠
- 2상모집 중단 (진행 중)· Relapsed/Refractory Small Cell Lung CancerA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
리드: 암젠
- 2상모집 중단 (진행 중)· Waldenstrom MacroglobulinemiaEfficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
협력: 암젠
- 2상모집 중단 (진행 중)· Premenopausal Idiopathic OsteoporosisRomosozumab/Denosumab Study for Premenopausal IOP
협력: 암젠
- 2상모집 중단 (진행 중)· Colorectal CancerPAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
협력: 암젠
- 2상모집 중단 (진행 중)· Multiple MyelomaDaratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
협력: 암젠, 얀센(J&J)
- 2상모집 중단 (진행 중)· Acute Lymphoblastic LeukemiaBlinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
협력: 암젠
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
협력: 암젠
- 2상모집 중단 (진행 중)· Multiple MyelomaStudy of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
협력: 암젠
- 2상모집 중단 (진행 중)· Plasma Cell MyelomaCarfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
협력: 암젠
- 2상모집 중단 (진행 중)· HER2-positive Breast CancerImpact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
협력: 암젠
- 2상모집 중단 (진행 중)· Smoldering Multiple MyelomaAggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
협력: 암젠
- 2상모집 중단 (진행 중)· SarcomaA Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
협력: 암젠, 머크(MSD)
- 2상모집 중단 (진행 중)· Breast CarcinomaCarboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
협력: 암젠
- 2상모집 중단 (진행 중)· Multiple MyelomaCarfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma
협력: 암젠
- 2상모집 중단 (진행 중)· Smoldering Multiple MyelomaCarfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
협력: 암젠
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.